AGIO

27.6004.03%
SG

Sarah Gheuens

Chief Medical Officer and Head of Research & Development

Dr. Sarah Gheuens, M.D., Ph.D., is Independent Director at Viridian Therapeutics, Inc. since September 2023. Dr. Gheuens is Chief Medical Officer of Agios Pharmaceuticals, Inc. from September 01, 2021 and serves as its Head of Research & Development since July 31, 2022. She previously served as Agios’ Head of clinical development for the genetically defined disease programs, as well as the Interim Head of regulatory affairs. Dr. Gheuens joined Agios in 2019, was promoted to CMO in 2021 and assumed leadership of the R&D organization in 2022. She has been instrumental in completing the pivotal Phase 3 program for pyruvate kinase deficiency and leading simultaneous regulatory submissions to the FDA and EMA in this indication, as well as designing the pivotal programs for thalassemia, sickle cell disease and the pediatric indications. Prior to joining Agios, Dr. Gheuens worked at Biogen, where she held roles of increasing responsibility in safety, medical affairs and clinical development. Her work was critical for the approval of SPINRAZA®. Before joining Biogen, Dr. Gheuens worked at Beth Israel Deaconess Medical Center (BIDMC), taking care of patients with HIV and neurological complications and doing research on progressive multifocal leukoencephalopathy. Dr. Gheuens received her medical degree from the Free University of Brussels (VUB), Belgium and completed her neurology residency at the University Hospital of the Free University of Brussels, Belgium, followed by an HIV/neurology fellowship at BIDMC, Boston, Mass., USA. She also holds a Ph.D. in Medical Sciences from the University of Antwerp, Belgium and a master’s in medical sciences from Harvard Medical School.

Positions